Effectiveness of Extracorporeal Shockwave in Planter Fasciitis

NCT07669831 | Completed

• 1 other identifier: HSH00071
• Study Type: observational
• Target: 175
• Locations: 1 country
• Sites: 1

Brief Summary

Extracorporeal Shockwave (ESW) is a popular, non-invasive approach that arisen in line to stimulate healing via acoustic waves targeting lesion site i.e., planter fasciitis. Therefore, current clinical trial targets to determine the long-term effectiveness of ESW on Calcaneal spur in terms of quality of life, functional, and clinical manifestations, as well addressing real barriers for ESW approach among whom diagnosed with planter fasciitis.

Conditions

Planter Fasciitis; Observational Cohort Study; Effectiveness; Extracoropral Shock Wave Therapy

Keywords

planter fasciitis; Quality of life; Extracorporeal Shock Wave Therapy; Effectiveness; Observational Cohort Study

Outcome Measures

Primary Outcomes (2)

• Pressure Pain Threshold

  A valid, reliable Pressure Algometer device, that is calibrated per each evaluation, in line to identify well-addressed pressure pain threshold, that spread from the plantar calcaneal tuberosity for each participant.

  1- At Baseline, 2- Post-Treatment, 3- After 6 months as long-term follow-up

• American Orthopedic Foot and Ankle Society Scale (AOFAS)

  a 9-item questionnaire classified into three subscales: 1) level of pain consists of 1 item and its score ranges from 0 to 40; 40 points = no pain and 0 points = severe pain; 2) function consists of 7 items (Activity limitations, support requirements, maximum continuous walking distance, walking surface, gait abnormalities, sagittal motion, hind foot motion, ankle hind-foot stability), and its score ranges from 0 (severe function impairment score) to 50 points (full function score); and 3) foot alignment consists of 1 item; its score ranges from 0 to 10 points; good alignment of ankle and foot equals 10 points and zero indicates severe malalignment, symptoms. It was used for measuring functional recovery after different foot and ankle problems. The total score of the scale ranged from 0 to 100 points; (0) indicates the worst, and (100) shows no symptoms or impairments.

  1- At baseline, 2- Post-treatment, 3- After 6 months as long-term follow-up.

Secondary Outcomes (2)

• Visual Analogue Scale

  1- At Baseline, 2- Post-Treatment, 3- After 6 months as long-term follow-up

• Arabic version of the foot function index (FFI)

  1- At Baseline, 2- Post-Treatment, 3- After 6 months as long-term follow-up

Study Arms (1)

Experimental Group

A 150 individuals with planter fasciitis whom received ESW intervention. Their age ranged between 25 to 59 years old, with well-organized full demographic data filling system, and evaluation for their clinical manifestations, plus service quality evaluation in line to address the long-term effectiveness of the received ESW therapeutic protocol, and identifying barriers they addressed.

Eligibility Criteria

• Age: 25 Years - 59 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64)
• Sampling Method: Probability Sample

Study Population

Current observational cohort trial involved participants diagnosed with planter fasciitis, whom age ranged between 25-59 years old, with nearby 3 months of clinical manifestations mainly heel pain. They had plantar medial heel pain: most noticeable with initial steps after a period of inactivity, but also worse following prolonged weight-bearing, * Whom had pain with palpation of the proximal insertion of the plantar fascia. * Whom had positive windlass test.

You may qualify if:

• Individuals diagnosed with planter fasciitis, whom age ranged between 25-59 years old, with nearby 3 months of clinical manifestations mainly heel pain.
• Whom have plantar medial heel pain: most noticeable with initial steps after a period of inactivity, but also worse following prolonged weight-bearing,
• Whom had pain with palpation of the proximal insertion of the plantar fascia.
• Whom had positive windlass test.

You may not qualify if:

• Any individual whom underwent feet or ankle surgical interventions, received steroid injections within the past 3 months, also whom have deep venous thrombosis, or had a tarsal tunnel syndrome, diabetic neuropathies or any sort of tumors, lymphatic lesions.

Sponsors & Collaborators

• Adly A Adam: lead

Study Sites (1)

Al-Kasr Al-Ani Hospitals

Cairo, Menofyia, 11432, Egypt

Location

Study Officials

• Adnan AA Gharib

  GOTHI

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: OTHER
• Target Duration: 6 Months
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: Physical Therapy Specialist

Study Record Dates

• First Submitted: June 21, 2026
• First Posted: June 25, 2026
• Study Start: April 1, 2024
• Primary Completion: January 1, 2026
• Study Completion: May 30, 2026
• Last Updated: July 7, 2026

Record last verified: 2026-07

Data Sharing

• IPD Sharing: Will not share

Locations

EG (1)